The
slide to be stained for CD15
comprised:
1. Kidney, 2-3. Hodgkin lymphoma classical type, NS. All tissues were fixed in 10 % neutral buffered formalin.
Criteria for assessing a CD15 staining as optimal included:
- A strong predominantly membranous
reaction of the epithelial cells lining the renal proximal
tubules.
- A strong and distinct predominantly
membranous staining as well as a dot-like (Golgi) staining of
the Hodgkin and Reed-Sternberg cells in the two cases of
Hodgkin lymphoma.
- A strong cytoplasmic staining of the
neutrophils in all three specimens.
- No or only a minimal background reaction.
121 laboratories participated in this
assessment. 76 % achieved a sufficient mark. In Table 1 the
antibodies (Abs) used and marks are summarized.
Table 1.
Abs and scores for CD15, run 25
|
Concentrated Abs |
N |
Vendor |
Optimal |
Good |
Borderl. |
Poor |
Suff.1 |
Suff. OPS2 |
|
mAb clone
MMA |
29
10
1 |
Becton Dickinson
NeoMarkers
Cell Margue |
21 |
8 |
6 |
5 |
73 % |
74 % |
|
mAb clone C3D-1 |
43 |
Dako |
9 |
22 |
5 |
7 |
72 % |
84 % |
|
mAb clone
Carb-3 |
11 |
Dako |
8 |
1 |
1 |
1 |
82 % |
82 % |
|
mAb clone BY87 |
2 |
Novocastra |
0 |
2 |
0 |
0 |
- |
- |
|
mAb clone H198 |
1 |
Becton
Dickinson |
1 |
0 |
0 |
0 |
- |
- |
|
mAb clone
MMA+BY87 |
1 |
Biocare Medical |
0 |
1 |
0 |
0 |
- |
- |
|
Ready-To-Use Abs |
|
|
|
|
|
|
|
|
|
mAb clone MMA |
18 |
Ventana |
3 |
11 |
3 |
1 |
78 % |
86 % |
|
mAb clone
Carb-3 |
5 |
Dako |
5 |
0 |
0 |
0 |
100 % |
100 % |
|
Total |
121 |
|
48 |
44 |
15 |
14 |
- |
- |
|
Proportion |
|
|
40 % |
36 % |
12 % |
12 % |
76 % |
81 % |
1) Proportion of sufficient stains
(optimal or good), 2) Proportion of sufficient stains with optimal
protocol settings only, see below.
The following central protocol parameters were used to obtain an
optimal staining:
Concentrated Abs
mAb clone MMA: The protocols giving an optimal result were
all based on heat induced epitope retrieval (HIER) using
Tris-EDTA/EGTA pH 9 (15/23)*, Cell Conditioning 1 (BenchMark,
Ventana) (2/3), Bond Epitope Retrieval Solution 2 (Bond, Leica)
(3/4), or Citrate pH 6 (1/2) as retrieval buffer. The mAb was
typically diluted in the range of 1:10 – 1:300 depending on the
total sensitivity of the protocol employed. Using these protocol
settings 29 out of 39 (74 %) laboratories produced a sufficient
staining (optimal or good).
* (number of optimal results/number of
laboratories using this buffer)
mAb
clone C3D-1: The protocols giving an optimal result were all
based on HIER using Tris-EDTA/EGTA pH 9 (6/22), Target Retrieval
Solution pH 9 (EnVision FLEX TRS high pH, Dako, (2/7) or EDTA/EGTA pH 8
(1/2). The mAb was diluted in the range of 1:5 – 1:20 depending on
the total sensitivity of the protocol employed. Using these protocol
settings 31 out of 37 (84 %) laboratories produced a sufficient
staining.
mAb clone Carb-3: The protocols giving an optimal result were
all based on HIER using Tris-EDTA/EGTA pH 9 (5/7), Target Retrieval
Solution pH 9 (EnVision FLEX TRS high pH, Dako, (1/1), Cell Conditioning 1
(BenchMark, Ventana) (1/2) or EDTA/EGTA pH 8 (1/1). The mAb was
typically diluted in the range of 1:50 – 400 depending on the total
sensitivity of the protocol employed. Using these protocol settings
9 out of 11 (82 %) laboratories produced a sufficient staining.
mAb clone H198: The protocol giving an optimal result was
based on heat induced epitope retrieval (HIER) using Citrate pH 6.
The Ab was diluted 1:20.
Ready-To-Use Abs
mAb clone MMA (prod. no 760-2504, Ventana): The protocols
giving an optimal result were based on HIER in Cell Conditioning 1,
standard, an incubation time of 32 min in the primary Ab and
UltraView as the detection system. Using these protocol settings 6
out of 7 (86 %) laboratories produced a sufficient staining.
mAb clone Carb-3 (prod. no IR062, Dako): The protocols giving
an optimal result were all based on HIER using Target Retrieval
Solution pH 9 (EnVision FLEX TRS high pH), an incubation time of 20 min in
the primary Ab and EnVision Flex as the detection system. Using
these protocol settings 5 out of 5 (100 %) laboratories produced a
sufficient staining.
The most frequent causes of insufficient staining were:
- Too low concentration of the primary antibody
- Insufficient HIER – too short heating time or use of citrate pH
6.0
- Inappropriate choice of epitope retrieval – proteolysis,
irrespective of the clone applied
- Use of a biotin based detection system complicating the
interpretation of kidney as positive control.
In this assessment and in concordance with the three previous runs
for CD15, virtually all laboratories were able to detect CD15 in the
neutrophil granulocytes, whereas the demonstration of CD15 in the
two Hodgkin lymphomas was more challenging and required a higher
sensitivity and a correctly calibrated protocol. In order to
validate a correct calibration of the immunohistochemical protocol
for CD15, kidney was a suitable control. In the optimally calibrated
protocols virtually all the epithelial cells of the proximal tubules
showed a strong and distinct predominantly membranous reaction,
indicating that these cells can serve as a reliable critical
staining quality indicator (CSQI) for CD15. However, kidney is only
a reliable positive control for CD15, when a non-biotin based
detection system is applied, as the non-specific reaction of
endogenous biotin in the renal tubules mimics the specific staining
reaction, which complicates the interpretation. 19 of the
participants (16 %) used a biotin based detection system out of which
8 (42 %) obtained a sufficient score.
Table 2:
Sufficient results with CD15 in four runs
This was the 4th assessment of CD15 in NordiQC. A constant increase
of the proportion of sufficient results has been seen, as shown in
table 2. Many factors contribute to this increase of sufficient
results, but the identification of kidney as CQSI and the tailored
recommendations given to the laboratories obtaining an insufficient
mark seem to be central for the improvement. From run 10 to run 25,
91 laboratories have been given a recommendation and submitted a
staining in the following run. 44 laboratories followed the
recommendations and 33 (75 %) improved to a sufficient mark, while 33
did not change their protocol and only 5 (15 %) improved their mark
to sufficient. 14 laboratories changed their entire system and 8 of
these (57 %) improved their mark to sufficient. The recommendations
given were typically: 1. Increase the concentration of the primary
Ab, 2. Use HIER with an alkaline buffer, and 3. consider change of
the primary Ab. Consequently, the mean concentration used for, e.g.,
the clone C3D-1 has changed from 1:40 in run 10 2004 to 1:20 in the
current run, and the proportion of laboratories using Citrate pH 6.0
has been reduced from 14 % in run 10 to 6 % in the current run.
The choice of Ab clone still seems to be an important parameter to
secure a robust immunohistochemical demonstration of CD15. The two
clones C3D-1 and MMA are still the most widely used and gave in this
assessment almost the same proportion of sufficient results of 72 %
and 73 % respectively. However the proportion of optimal results was
markedly higher for the clone MMA than the clone C3D-1: 53 % of the
protocols based on the clone MMA resulted in an optimal staining
versus 21 % for C3D-1 (also see table 1). Clone MMA in a RTU format
gave a lower proportion of optimal results than the concentrated
format. The newly introduced clone Carb-3 (Dako) seems to be very
robust and provided a high number of optimal results both applied in
the concentrated format and as RTU.
The main provider of the clone MMA, Becton Dickinson, has not CE IVD
labelled their product and only Ventana and LabVision have CE IVD
registered their clone MMA. NordiQC highly recommends to use clone
MMA as CE IVD labelled or change to another IVD Labelled clone as Carb-3.
Conclusion
The mAbs clones MMA, C3D-1 and Carb-3 are all useful markers for
CD15.
HIER preferable in an alkaline buffer seems to be mandatory to have
an optimal reaction for CD15. Kidney is recommended as positive
control: The epithelial cells lining the renal proximal tubules
shall show a strong predominantly membranous reaction and can thus
serve as CSQI for CD15, provided that a non-biotin based detection
system is used.
|